Cannabis Use in Cancer: A Survey of the Current State at BC Cancer before Recreational Legalization in Canada
Hawley et al.·Current OncologyImpact 2.9
UnklarGRADENiedrig40 Zitate
Stichproben = 821 Pat.
DauerQuerschnittsbefragung an einem…
EndpunktPrävalenz des Cannabiskonsums
Verblindungn.a.
DesignQuerschnittsbefragung
”Kernaussage
23% der Befragten nutzen derzeit Cannabis überwiegend für medizinische Zwecke zur Symptomkontrolle (Schmerz, Schlaflosigkeit, Übelkeit, Angst); es handelt sich um eine deskriptive Prävalenzstudie ohne Interventionsvergleich oder Effektivitätsmessung.
Zusammenfassung
Querschnittsbefragung unter n=821 Krebspatienten in British Columbia (Rücklaufquote 27,4%); 23% nutzen aktuell Cannabis-Produkte (überwiegend medizinisch), 28% waren Vornutzer (meist Freizeit). Symptomziele bei aktuellen Nutzern: Schmerz, Schlaflosigkeit, Übelkeit, Angst; viele hofften zusätzlich auf antikanzerogene Effekte. Nur 31% der aktuellen Nutzer hatten medizinische Autorisierung.
P
PopulationKrebspatienten an 6 BC Cancer-Standorten (Kanada) vor der Freizeitlegalisierung, n=821 (Rücklaufquote 27,4% von 2998 angeschriebenen Patienten)
I
InterventionCannabiskonsum (medizinisch und/oder zu Freizeitzwecken, verschiedene Applikationsformen) – Selbstbericht
O
Outcome23% der Befragten konsumierten aktuell Cannabis (fast ausschließlich medizinisch), weitere 28% hatten es früher konsumiert; häufigste Zielindikationen: Schmerz, Insomnie, Übelkeit und Angst; nur 31% der aktuellen Nutzer besaßen eine medizinische Genehmigung
Vertrauen in die Evidenz
Sehr niedrigNiedrigModeratHoch
Niedrig
Zweite von vier GRADE-Stufen, die Effektschätzung ist begrenzt verlässlich.
Background: Cancer patients experience multiple symptoms throughout their illness, and some report benefit from the use of cannabis. There are concerns that many patients are accessing products inappropriate for their situation and potentially putting themselves at risk. In the present study, we aimed to capture the prevalence of cannabis use among cancer patients at BC Cancer before recreational legalization in Canada and to identify the reasons that patients take cannabis, the various routes of administration they use, and the reasons that prior users stopped.
Methods: Patients were eligible if, on the selected study day (15 August 2018), they were scheduled for an appointment at any of the 6 BC Cancer sites. Eligible patients were mailed a survey.
Results: Of surveys sent to 2998 patients, 821 (27.4%) were returned and included in analysis. Of those respondents, 23% were currently using cannabis-based products, almost exclusively for medical purposes, and an additional 28% had been users in the past (most often recreationally). Of the patients currently using cannabis, 31% had medical authorization. The most common symptoms that the current users were targeting were pain, insomnia, nausea, and anxiety; many were also hoping for anticancer effects.
Conclusions: More than half the respondents had tried cannabis at some time, and almost one quarter of respondents were currently taking cannabis to help manage their symptoms or treat their cancer, or both. Many more patients would consider use with appropriate guidance from a health care professional. More research is needed to inform physicians and patients about safe uses and doses and about the potential adverse effects of cannabis use.